$3.55
-0.40-10.05%
Last update: Nov 10, 11:06 AM
Aligos Therapeutics Inc
ALGSNASDAQ
Aligos Therapeutics fell 42.6% from $6.89 to $3.95, behind the S&P 500's +10.5%. Its worst day was Aug 31 (−15.2%), and its low came Nov 9 at $3.95.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Aligos Therapeutics closed at its highest level of the year, 93.1% above where the year started.
+15.5% · S&P 500 −1.1%
EPS of $-1.91 beat the $-2.33 estimate on $169,000.00 revenue (est. $266,670.00).
Story events cover the past 12 months · Times ET
−2.9% · S&P 500 −0.6%
Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infectionHBeAg- cohort sample size increased to optimize powering; futility criteria not metStudy drugs were
−15.1% · S&P 500 +0.8%
EPS of $-2.21 beat the $-2.29 estimate on $2.8M revenue (est. $333,330.00).
+6.8% · S&P 500 +0.8%
EPS of $-0.14 beat the $-1.28 estimate on $0.00 revenue (est. $18.9M).
+16.2% · S&P 500 −0.2%
Aligos Therapeutics shares fell 15.2%, while the S&P 500 fell 0.3%.
−15.2%, the year's worst day · S&P 500 −0.3%
EPS of $-2.09 beat the $-2.51 estimate on $2.8M revenue (est. $5.0M).
−9.8% · S&P 500 +0.3%
Where it ended: a close of $3.95 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 4, 2027 (EPS est. $-1.70, revenue est. $683,330.00).
Nothing in the past 12 months.
All ALGS dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ALGS and SPY from Benzinga historical bars. Not investment advice.
